Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $9.9B | $9.8B | $9.7B | $9.8B | $10.2B | $11.0B | $13.4B | $14.4B | $13.5B | $12.3B | $11.4B | $10.8B | $9.7B | $6.9B | $5.5B | $5.0B | $4.7B | $4.4B | $4.1B | $3.2B | $2.7B |
| Bruttoergebnis | $7.1B | $6.9B | $7.4B | $7.3B | $7.9B | $8.9B | $11.6B | $12.4B | $11.6B | $10.6B | $10.0B | $9.5B | $8.5B | $6.1B | $5.0B | $4.6B | $4.3B | $4.0B | $3.7B | $2.8B | $2.4B |
| Bruttomarge % | 71.7% | 70.5% | 76.1% | 74.2% | 77.6% | 80.8% | 86.6% | 86.4% | 86.5% | 86.7% | 87.5% | 88.5% | 87.9% | 87.6% | 90.1% | 90.8% | 91.5% | 91.3% | 90.2% | 89.4% | 89.8% |
| Betriebsergebnis (EBIT) | $1.4B | $1.9B | $2.5B | $2.1B | $2.9B | $2.8B | $4.6B | $7.0B | $5.9B | $5.3B | $5.2B | $4.9B | $4.0B | $2.5B | $1.8B | $1.7B | $1.2B | $1.3B | $1.2B | $780M | $440M |
| Operative Marge % | 14.4% | 19.1% | 25.7% | 21.3% | 28.4% | 25.4% | 34.2% | 49.0% | 43.8% | 43.5% | 45.0% | 45.4% | 40.9% | 36.3% | 33.3% | 34.2% | 26.5% | 29.6% | 29.6% | 24.6% | 16.4% |
| Jahresüberschuss | $836M | $1.3B | $1.6B | $1.2B | $3.0B | $1.6B | $4.0B | $5.9B | $4.4B | $2.5B | $3.7B | $3.5B | $2.9B | $1.9B | $1.4B | $1.2B | $1.0B | $970M | $783M | $638M | $218M |
| Nettomarge % | 8.4% | 13.2% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% | 33.0% | 30.2% | 26.9% | 25.0% | 24.4% | 21.3% | 22.2% | 19.1% | 20.1% | 8.1% |
| EBITDA | — | $3.1B | $3.0B | $2.4B | $3.5B | $3.9B | $5.1B | $7.7B | $7.0B | $6.6B | $6.3B | $5.6B | $4.6B | $3.0B | $2.2B | $2.1B | $1.6B | $1.8B | $1.7B | $1.3B | $869M |
| Ergebnis je Aktie (EPS) | $5.65 | $8.82 | $11.19 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.92 | $15.34 | $12.37 | $7.81 | $5.76 | $5.04 | $3.94 | $3.35 | $2.65 | $1.99 | $0.63 |
| Ausstehende Aktien (Mio.) | — | 147M | 146M | 146M | 146M | 150M | 161M | 187M | 205M | 213M | 219M | 231M | 237M | 238M | 240M | 245M | 255M | 289M | 295M | 320M | 345M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für BIIB. /companies/us/BIIB
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms